SiNtx Technologies Inc

SiNtx Technologies Inc.: Small‑cap biomaterial medical devices, $9.89 M market cap, negative P/E, growth‑stage focus on silicon‑nitride spinal and joint implants—track FDA approvals and earnings for upside.

SiNtx Technologies

SiNtx Technologies launches OsseoSculpt, a silicon‑nitride bone‑healing biologic for its SINAPTIC ankle system, while securing a private‑label deal to expand market reach.

SiNtx Technologies Inc. has published a groundbreaking study demonstrating the broad-spectrum antiviral activity of its silicon nitride technology against coronaviruses, leading to a significant increase in the company’s stock price.

SiNtx Technologies Inc. is struggling financially and faces an uncertain future in the competitive health care sector, with a negative earnings outlook and a declining stock price.

SiNtx Technologies Inc. has reported a decline in stock price, with a recent close of $3.3082, amidst financial challenges and a negative price-to-earnings ratio, despite its innovative approach in the health care sector.